Please assess the completion status of the following clinical trial:

Trial Title: Aliskiren for Immunoglobulin A (IgA) Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 18-65 years~* requires anti-hypertensive therapy~* renal biopsy within the past 3 years and confirmed the diagnosis of IgA nephropathy~* proteinuria \> 1 g/day (or proteinuria \> 1 g/g-Cr) in 3 consecutive samples within 12 weeks despite ACE inhibitor or ARB treatment for at least 3 months~* estimated glomerular filtration rate \> 30 ml/min/1.73m2~* willingness to give written consent and comply with the study protocol~Exclusion Criteria:~* Patients who are diabetic, and patients with systemic diseases that may cause IgA nephropathy or another nephropathy.~* Pregnancy, lactating or childbearing potential without effective method of birth control~* Severe gastrointestinal disorders that interfere with their ability to receive or absorb oral medication~* History of malignancy, including leukemia and lymphoma within the past 2 years~* Systemic infection requiring therapy at study entry~* Any other severe coexisting disease such as, but not limited to, chronic liver disease, myocardial infarction, cerebrovascular accident, malignant hypertension~* History of drug or alcohol abuse within past 2 years~* Participation in any previous trial on aliskiren or other renin inhibitor~* Previous treatment with fish oil, steroid, cytotoxic agents, or aldosterone antagonist~* History of treatment with other drugs that may affect proteinuria within past 2 years~* Patients receiving treatment of corticosteroid~* On other investigational drugs within last 30 days~* History of a psychological illness or condition such as to interfere with the patient's ability to understand the requirement of the study~* History of non-compliance~* Known history of sensitivity or allergy to aliskiren or other renin inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): each subject will receive oral aliskiren 300 mg/day for 16 weeks, followed by a washout period of 4 weeks, then crossed over to placebo for another 16 weeks
- II (Type: ACTIVE_COMPARATOR): each subject will receive placebo for 16 weeks, followed by a washout period of 4 weeks, then crossed over to oral aliskiren 300 mg/day for another 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).